ctDNA detection has advanced, allowing identification of minimal residual disease and predicting cancer recurrence with high sensitivity. Liquid biopsies offer a minimally invasive method to analyze ...

Validation of LOH-Germline Inference Calculator of Variant Origin on Real-World Data of Prevalence of Germline and Somatic BRCA1/2 Mutations in High-Grade Serous Ovarian Cancer in Serbia ctDNA-based ...

Toronto, Ontario--(Newsfile Corp. - December 11, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a leader in the development of diagnostic and prognostic tests for ...

Breast cancer takes the lives of over 43,000 people in the USA annually and 685,000 worldwide 1,2. Although the majority of patients are initially diagnosed with early-stage, curable disease, 20–30% ...

Nicholas Hornstein, MD, PhD discusses ctDNA in colorectal cancer, the INTERCEPT-TT trial, building Northwell's GI oncology program, and what better drugs will look like.

Breast cancer relapse often begins long before it can be seen. Tiny clusters of residual tumor cells may persist after treatment, quietly driving recurrence while remaining invisible to conventional ...

Despite major therapeutic advances, breast cancer remains prone to recurrence, particularly in patients with early-stage disease who appear disease-free after treatment. Follow-up care still relies ...

Natera NTRA recently announced that Signatera has received PMDA approval in Japan for use in colorectal cancer (CRC) patients ...

Researchers hope the resulting datasets will be a resource to help discover how to eliminate persister cells before they can give rise to drug-resistant disease.

This Collection supports and amplifies research related to SDG 3: Good Health & Wellbeing. Liquid biopsies show promising potential to detect and characterize minimal residual disease (MRD) and ...

A research team led by Prof. Liu Qingsong at the Institute of Health and Medical Technology, the Hefei Institutes of Physical ...